247 related articles for article (PubMed ID: 16571820)
21. In vivo role of complement-interacting domains of herpes simplex virus type 1 glycoprotein gC.
Lubinski J; Wang L; Mastellos D; Sahu A; Lambris JD; Friedman HM
J Exp Med; 1999 Dec; 190(11):1637-46. PubMed ID: 10587354
[TBL] [Abstract][Full Text] [Related]
22. Neutralization of vesicular stomatitis virus (VSV) by human complement requires a natural IgM antibody present in human serum.
Beebe DP; Cooper NR
J Immunol; 1981 Apr; 126(4):1562-8. PubMed ID: 6259260
[TBL] [Abstract][Full Text] [Related]
23. Interactions of a nonneutralizing IgM antibody and complement in parainfluenza virus neutralization.
Vasantha S; Coelingh KL; Murphy BR; Dourmashkin RR; Hammer CH; Frank MM; Fries LF
Virology; 1988 Dec; 167(2):433-41. PubMed ID: 2849234
[TBL] [Abstract][Full Text] [Related]
24. Herpes simplex virus glycoprotein C: molecular mimicry of complement regulatory proteins by a viral protein.
Huemer HP; Wang Y; Garred P; Koistinen V; Oppermann S
Immunology; 1993 Aug; 79(4):639-47. PubMed ID: 8406590
[TBL] [Abstract][Full Text] [Related]
25. Human antibodies to herpes simplex virus type 1 glycoprotein C are neutralizing and target the heparan sulfate-binding domain.
Adamiak B; Trybala E; Mardberg K; Johansson M; Liljeqvist JA; Olofsson S; Grabowska A; Bienkowska-Szewczyk K; Szewczyk B; Bergstrom T
Virology; 2010 May; 400(2):197-206. PubMed ID: 20176392
[TBL] [Abstract][Full Text] [Related]
26. Interactions of human complement with virus particles containing the Nipah virus glycoproteins.
Johnson JB; Aguilar HC; Lee B; Parks GD
J Virol; 2011 Jun; 85(12):5940-8. PubMed ID: 21450814
[TBL] [Abstract][Full Text] [Related]
27. Herpes simplex virus type 1 glycoprotein gC mediates immune evasion in vivo.
Lubinski JM; Wang L; Soulika AM; Burger R; Wetsel RA; Colten H; Cohen GH; Eisenberg RJ; Lambris JD; Friedman HM
J Virol; 1998 Oct; 72(10):8257-63. PubMed ID: 9733869
[TBL] [Abstract][Full Text] [Related]
28. Direct binding of herpes simplex virus type 1 virions to complement C3.
Chen YT; Wang YH; Cheng YY; Hung SL
Viral Immunol; 2003; 16(3):347-55. PubMed ID: 14583149
[TBL] [Abstract][Full Text] [Related]
29. Immune evasion by herpes simplex virus type 1, strategies for virus survival.
Friedman HM
Trans Am Clin Climatol Assoc; 2003; 114():103-12. PubMed ID: 12813914
[TBL] [Abstract][Full Text] [Related]
30. Natural antibody--complement dependent neutralization of bovine herpesvirus 4 by human serum.
Machiels B; Gillet L; Nascimento Brito SD; Drion P; Delforge C; Nizet Y; Gianello P; Bona C; Costes B; Markine-Goriaynoff N; Vanderplasschen A
Microbes Infect; 2007; 9(14-15):1530-7. PubMed ID: 18024120
[TBL] [Abstract][Full Text] [Related]
31. Cloning and expression of the complement receptor glycoprotein C from Herpesvirus simiae (herpes B virus): protection from complement-mediated cell lysis.
Huemer HP; Wechselberger C; Bennett AM; Falke D; Harrington L
J Gen Virol; 2003 May; 84(Pt 5):1091-1100. PubMed ID: 12692273
[TBL] [Abstract][Full Text] [Related]
32. Implications for herpes simplex virus vaccine strategies based on antibodies produced to herpes simplex virus type 1 glycoprotein gC immune evasion domains.
Chang YJ; Jiang M; Lubinski JM; King RD; Friedman HM
Vaccine; 2005 Sep; 23(38):4658-65. PubMed ID: 15936852
[TBL] [Abstract][Full Text] [Related]
33. Higher Throughput Quantification of Neutralizing Antibody to Herpes Simplex Viruses.
Blevins TP; Mitchell MC; Korom M; Wang H; Yu Y; Morrison LA; Belshe RB
PLoS One; 2015; 10(12):e0144738. PubMed ID: 26658766
[TBL] [Abstract][Full Text] [Related]
34. Studies on the mechanism of bacterial resistance to complement-mediated killing. VI. IgG increases the bactericidal efficiency of C5b-9 for E. coli 0111B4 by acting at a step before C5 cleavage.
Joiner KA; Goldman RC; Hammer CH; Leive L; Frank MM
J Immunol; 1983 Nov; 131(5):2570-5. PubMed ID: 6355297
[TBL] [Abstract][Full Text] [Related]
35. Neutralizing antibody to herpes simplex virus by a novel neutralization method with peroxidase-labelled complement Clq.
Taguchi F; Kawasaki T; Matsuzaki T; Lee SM
J Virol Methods; 1991 May; 32(2-3):157-62. PubMed ID: 1651947
[TBL] [Abstract][Full Text] [Related]
36. Blocking immune evasion as a novel approach for prevention and treatment of herpes simplex virus infection.
Judson KA; Lubinski JM; Jiang M; Chang Y; Eisenberg RJ; Cohen GH; Friedman HM
J Virol; 2003 Dec; 77(23):12639-45. PubMed ID: 14610186
[TBL] [Abstract][Full Text] [Related]
37. Activation of the fifth and sixth components of the human complement system: C6-dependent cleavage of C5 in acid and the formation of a bimolecular lytic complex, C5b,6a.
Hammer CH; Hänsch G; Gresham HD; Shin ML
J Immunol; 1983 Aug; 131(2):892-8. PubMed ID: 6863934
[TBL] [Abstract][Full Text] [Related]
38. Complement component C3b binds directly to purified glycoprotein C of herpes simplex virus types 1 and 2.
Eisenberg RJ; Ponce de Leon M; Friedman HM; Fries LF; Frank MM; Hastings JC; Cohen GH
Microb Pathog; 1987 Dec; 3(6):423-35. PubMed ID: 2849025
[TBL] [Abstract][Full Text] [Related]
39. Expression and characterization of herpes simplex virus type 1 (HSV-1) glycoprotein G (gG) by recombinant vaccinia virus: neutralization of HSV-1 infectivity with anti-gG antibody.
Sullivan V; Smith GL
J Gen Virol; 1987 Oct; 68 ( Pt 10)():2587-98. PubMed ID: 2822841
[TBL] [Abstract][Full Text] [Related]
40. Differential mechanisms of complement-mediated neutralization of the closely related paramyxoviruses simian virus 5 and mumps virus.
Johnson JB; Capraro GA; Parks GD
Virology; 2008 Jun; 376(1):112-23. PubMed ID: 18440578
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
